Steward Partners Investment Advisory LLC Trims Position in Smith & Nephew plc (NYSE:SNN)
Steward Partners Investment Advisory LLC lessened its stake in Smith & Nephew plc (NYSE:SNN) by 69.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 879 shares of the medical equipment provider’s stock after selling 2,031 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Smith & Nephew were worth $42,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of SNN. Whittier Trust Co. purchased a new position in shares of Smith & Nephew in the third quarter valued at $26,000. AdvisorNet Financial Inc raised its position in Smith & Nephew by 82.4% in the third quarter. AdvisorNet Financial Inc now owns 664 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. LS Investment Advisors LLC purchased a new position in Smith & Nephew in the second quarter worth $31,000. Advisory Services Network LLC raised its position in Smith & Nephew by 132.7% in the second quarter. Advisory Services Network LLC now owns 819 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 467 shares in the last quarter. Finally, Oakworth Capital Inc. purchased a new position in Smith & Nephew in the second quarter worth $42,000. 9.11% of the stock is currently owned by institutional investors.
A number of research analysts have recently weighed in on SNN shares. ValuEngine cut Smith & Nephew from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Sanford C. Bernstein started coverage on Smith & Nephew in a research report on Tuesday. They issued an “outperform” rating for the company. Berenberg Bank upgraded Smith & Nephew from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Finally, Zacks Investment Research upgraded Smith & Nephew from a “sell” rating to a “hold” rating in a research report on Saturday, November 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Smith & Nephew currently has a consensus rating of “Hold” and a consensus price target of $27.50.
The business also recently disclosed a — dividend, which was paid on Wednesday, October 30th. Investors of record on Friday, October 4th were given a dividend of $0.288 per share. This represents a yield of 1.5%. The ex-dividend date of this dividend was Thursday, October 3rd. Smith & Nephew’s dividend payout ratio is presently 27.72%.
Smith & Nephew Company Profile
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
See Also: 52-week highs
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN).
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.